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Abstract
Background: Trauma is one of the leading causes of death in young adult patients. Many pre-clinical and clinical
studies attempt to investigate the immunological pathways involved, however the true mediators remain to be
elucidated. Herein, we attempt to describe the immunologic response to systemic trauma in the context of the
Danger model.
Data Sources: A literature search using PubMed was used to identify pertinent articles describing the Danger
model in relation to trauma.
Conclusions: Our knowledge of Danger signals in relation to traumatic injury is still limited. Danger/alarmin signals
are the most proximal molecules in the immune response that have many possibilities for effector function in the
innate and acquired immune systems. Having a full understanding of these molecules and their pathways would
give us the ability to intervene at such an early stage and may prove to be more effective in blunting the post-
injury inflammatory response unlike previously failed cytokine experiments.
Introduction
The immune system has two effector arms, innate and
adaptive, which mediate the response to pathogens and
injury. The innate system is a non-specific response while
the adaptive system is pathogen and antigen specific. This
system has evolved to respond appropriately to pathogen
or injury, but may be maladaptive in the setting of over-
whelming injury as seen in complex traumatic war wounds
or multisystem civilian trauma. In the setting of severe
traumatic injury, the immune system is overwhelmed by
the massive release of endogenous signals from injured tis-
sue. Once systemically activated, the immune system
reacts against the host, potentiating tissue damage and
leading to organ failure [1]. In this situation, the immuno-
logic response to injury, not the actual injury itself, leads
to undue morbidity, and in some cases mortality.
While immune mediated responses have classically
been thought to center on self and non-self interactions
and thereby neglect most traumatic injuries, the Danger
model abandons this classical concept [2]. The Danger
model theorizes that the immune system’s primary driv-
ing force is the need to detect and protect against dan-
ger and does not discriminate between self and non-self
[2]. This concept states that the mechanism by which a
cell dies governs whether the immune response is
initiated. Therefore, tissue damage or an injury or endo-
genous signals of cell distress can trigger both an innate
and adaptive response only if it causes danger, a non-
controlled and abnormal cell death process unlike apop-
tosis. In the absence of danger, host tissues remain
healthy or undergo apoptotic death and are scavenged,
and no immune response occurs. In contrast, when an
infectious or sterile insult causes cell damage, lysis or
apoptosis with release of intracellular contents an
immune response is initiated” [3]. Thus, the immune
system is governed from within, responding to endogen-
ous signals that originate from stressed or injured cells.
Severe multi-system trauma can result in the systemic
activation of the innate immune system [4]. This may
result in a detrimental self-aggressive immunologic
response with subsequent secondary infection, sepsis
and multiple organ dysfunction (Figure 1). Various
immune cell-derived mediators are produced and
released during trauma, including complement factors,
coagulation system factors, acute phase proteins, and
neuroendocrine mediators, which have been shown to
play a major role in systemic inflammation [1]. These
Danger signals can activate innate immune responses
after trauma [5] and also act as the initiator of further
downstream effector responses through their liberation
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review, we attempt to describe the immunologic
response to systemic trauma in the context of the Dan-
ger model with a review of the key mediators in support
of this paradigm. The understanding of this response
may have broad implications in the management of the
severely injured patient.
The Danger Model
Traditional theories of immune regulation stems from
t h ew o r ko fS i rF r a n kM a c f a r l a n eB u r n e t[ 6 , 7 ] .B u r n e t
postulated that immune cells have the ability to distin-
guish between self and non-self antigens to allow for
activation and clonal selection of the adaptive immune
system [8,9]. However, it was recognized that the innate
immune system played a crucial role in contributing to
adaptive immune response activation through antigen
presenting cells and its regulation of co-stimulatory
molecules [3,10,11]. Janeway expanded the classical ver-
sion of the self/non-self model through his discovery of
evolutionarily primitive receptors called pattern recogni-
tion receptors (PRRs) that are able to recognize and
Figure 1 Immunologic Response to Severe Trauma.
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gen associated molecular patterns (PAMPs) [12-14].
These PAMPs allow for differentiation of infectious anti-
gens from noninfectious ones based on the antigen’s
association with infection [13]. However, it was recog-
nized that this concept of response to primarily exogen-
ous stimuli such as foreign antigen or bacteria was
inadequate to describe other situations such as tumors
and autoimmunity, and the focus of this discourse,
trauma [3,13]. In an attempt to address this conceptual
deficit, a modification of the self/non-self paradigm, the
Danger Theory, was introduced which clarifies the
immune response in the setting of traumatic injury.
The Danger Theory, proposed by Matzinger in 1994,
suggests that the function of immune system is to pre-
vent and recognize attack from harm in the context of
“Danger signals” [2]. Danger theorists believe the
mechanism by which a cell dies governs whether an
immune response is initiated and that the immune sys-
tem does not respond to non-self but rather from Dan-
ger signals from injured/dying cells [2,3]. Matzinger has
argued that the immune system is governed from within
through endogenous signals, later defined as alarmins,
originating from cells being stressed, signifying damage
[3]. Thus, inflammation in terms of the danger therapy
can be considered the result of immune activation from
both exogenous and endogenous danger/alarm signals.
Seong and Matzinger later expanded this idea by pro-
posing that both PAMPs and “alarmins” have similar
conserved hydrophobic portions on their respective
molecules, thus able to engage the same pattern recog-
nition receptors to elicit comparable noninfectious
inflammatory responses [15]. Due to their similarities,
“alarmins” (which respond to endogenous signals) and
PAMPs (which respond to exogenous signals) are classi-
fied as danger associated molecular patterns (DAMPs)
to signify the close relationship between trauma and
pathogen evoked inflammatory responses [16].
The immune response to microbial infection has a
striking resemblance to the one seen in trauma. In fact,
the profile of cytokine and chemokine production has
been shown to be similar in the inflammatory response
between sterile injury and bacterial infection [17,18].
These pathways are shared in that many endogenous
Danger signals released during infection and sterile
injury such as high mobility box group 1 (HMGB1),
heat shock proteins (Hsp), and hyaluronan have been
implicated to elicit an intrinsic inflammatory immune
response through similar pattern recognition receptors
[19,20]. Understanding the different Danger signals
involved in sterile injury along with their mechanism
may lead to possible areas of intervention and manipula-
tion of immune responses as future therapeutic
modalities.
Singnals & Mechanism
The release of endogenous intracellular and extracellular
molecules specifically generated upon tissue injury sig-
nals the threat of either infection or injury [21]. Potent
immune cell activation can be mediated by so called
damage associated molecular patterns via pattern recog-
nition receptors (PPRs) such as Toll-like receptors
(TLRs). TLRs represent a key molecular link between
tissue injury, infection, and inflammation. Moreover,
DAMPs have also been implicated in diseases where
excessive inflammation plays a key role in pathogenesis
[21]. Rock and Kono [13] outlined four fundamental
biological outcomes that a DAMP must fulfill.
1 )T h ep u r i f i e dm o l e c u l es h o u l dc a u s ea ni n f l a m m a -
tory response when injected into a living organism.
2) The purified molecule should also be active at nor-
mal physiological concentrations.
3) Microbial contamination should be ruled out as the
source of inflammatory response. This is especially
important in DAMPs that work through Toll-like recep-
tors (TLRs), since these are known to sense microbial
products.
4) Eliminating or neutralizing the molecule from dead
cells should reduce the inflammatory response. This last
criterion is most likely the hardest since it is likely that
multiple extracellular matrix and/or endogenous intra-
cellular molecules are released by activated or necrotic
cells upon injury or degraded following tissue damage.
There are many molecules that have been identified as
danger associated molecular patterns in the literature to
include but not limited to HMGB1, Hsp, uric acid (UA),
galectins, thioredoxin, adenosine, etc. [13], but here we
will only examine four of the most common and well-
defined, as well as their interactions with the members
of the TLR family of receptors.
High Mobility Group Box 1
HMGB1 is a nuclear non-histone chromosomal protein
that binds to DNA causing it to bend [7]. While intra-
cellular HMGB1 stabilizes nucleosome formation and
facilitates transcription, its extracellular release in
response to inflammatory stimuli and/or tissue damage
and its role as a known danger/alarmin signal-activator
of innate immunity, is of interest. When released extra-
cellularly HMGB1 functions as a potent cytokine-like
factor driving the initiation and perpetuation of other
proinflammatory mediators, inducing cell-mediated
inflammatory (Th1 type) responses, and serves as well
as a chemo-attractant for immature dendritic cells
which process and present antigen [22]. In contrast to
necrotic cells, cells undergoing apoptosis retain HMGB1
irreversibly bound to their chromatin and do not sup-
port inflammation [23]. When a few apoptotic cells are
cleared by macrophages, HMGB1 is released but does
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ever, when a large number of apoptotic cells are cleared
in this pattern, there is a large level of HMGB1 passively
released in addition to that actively secreted from a vari-
ety of HMGB1 secreting cell types following this inflam-
matory stimulus [16]. In contrast, when cell membrane
integrity is lost, as happens with tissue injury or cell
necrosis, HMGB1 is released into extracellular space
and signals danger to the surrounding cells (Figure 2).
Active secretion acts as a pro-inflammatory cytokine
during an immunological challenge, orchestrating a
defensive inflammatory response to ischemia, burn,
infection or sepsis and initiate tissue regeneration [25].
In vitro, HMGB1 released from necrotic cells stimulated
production of TNF-a, a pro-inflammatory cytokine [13].
Tsung et al. [26] demonstrated that injection of HMGB1
increased tissue damage after hepatic ischemia reperfu-
sion injuries. It has also been demonstrated that admin-
istration of HMGB1 antibodies reduced inflammation
and provided some protection from injury in both
ischemic reperfusion [26] and thermal burns [27]. There
is some concern that the inflammatory reaction
stimulated directly by HMGB1 is inconsistently repro-
duced [16]. Some studies have shown that HMGB1
injected into the heart after an infarction can promote
regeneration and recovery of the cardiac performance
[28]. Although this goes against the fourth tenet defin-
i n gaD A M P ,t h i si ss i m p l yt h ee n dr e s u l tw h i c h
involves a complex pathway involving RAGE receptor
interrogation and c-kit+ cardiac cells that play a key
role in cell proliferation and differentiation in vivo [28].
Preventing, blocking and/or neutralizing HMGB1 release
by injured cells is a compelling active area of research
focus and could potentially become a therapeutic avenue
for intervention.
While HMGB1 can influence the initiation of both
innate and adaptive immune responses, the mechanism
by which HMGB1 functions as a DAMP is poorly
defined. Huang et al. [27] demonstrate that the antibody
against the receptor for advanced glycation end products
(RAGE) inhibits the ability of HMGB1 to promote
inflammation. This implicates RAGE as a receptor that
binds HMGB1 and signals inflammation. Similarly,
S100A12 and S100B, a subset of calcium binding
Figure 2 Mechanism of HMGB1 (DAMP) Release and Immune Cell Activation.
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RAGE to induce a specific inflammatory pattern with
increased vascularity in endothelial cells and a pro-
thrombotic effect, although these effector functions pre-
sence after HMGB1 activtion is yet to be determined
[16]. The same group has demonstrated that administer-
ing HMGB1 blocking agents, such as ethyl pyruvate or
anti-RAGE, can significantly reduce serum levels of
HMGB1 and restore the expression levels of IL-2 and
IL-2a, which mediate expansion of T-cells, key players
in the adaptive response. In this study the expression
levels of CD152 and Foxp3 were elevated on splenic reg-
ulatory T cells, but expression levels of both markers
were reduced in groups that were administered ethyl
pyruvate or anti-RAGE [27]. With respect to the early
inflammatory response Tsung et al. [26] demonstrated
that tissue damage caused by hepatic ischemia was
decreased when mice were treated with neutralizing
antibodies against HMGB1. Endogeneous tissue damage
was worsened when additional exogenous HMGB1, in
the form of recombinant HMGB1, was administered to
mice after hepatic ischemic injuries [26]. This demon-
strates that HMGB1 acts as an early danger/alarmin sig-
nal and mediator of tissue injury and trauma in liver
ischemia [26]. This could be extrapolated out to surgical
trauma but this has yet to be demonstrated in pre-clini-
cal models. HMGB1 has already been proven to be a
successful therapeutic target in experimental models of
infectious and inflammatory disorders including sepsis,
cancer and theumatoid arthritis [25], we are getting clo-
ser to isolating this molecule as a target for therapeutic
manipulation in trauma.
Heat Shock Proteins
Hsp are intracellular cytoprotective chaperone proteins
that play key roles in intracellular trafficking, protein
folding and maintenance of protein integrity during nor-
mal and stress-induced environmental conditions [29].
Hsp’s are released from a variety of cell types, present
on cell surfaces and found in the serum [30]. The upre-
gulation and extracellular release of heat shock proteins
acts as a Danger signal in response to stresses involving
cell necrosis from innate immune reactions encompass-
ing bacterial infections/antigen and/or the clearance of
neoplastic-transformed cells [29]. When released in
response to stress Hsp’s provide protection against
apoptosis via both upstream and downstream pathways
[31]. This potentially allows the cell to continue an
inflammatory response. Prohaska et al [32]. reported
that stressed-induced extracelleular Hsp70 induces pro-
inflammatory responses in human monocytes [32].
Hsp70 released into the extracellular milieu specifically
binds to Toll-like receptors (TLR2 and TRL4) on anti-
gen-presenting cells (APC) through a CD14-dependent
pathway and exerts immunoregulatory effects, including
the upregulation of adhesion molecules, co-stimulatory
molecule expression, and cytokine and chemokine secre-
tion [33]. Interestingly, dendritic cells are capable of dis-
tinguishing the stressed apoptotic cells versus the non-
stressed cells based on the presence of heat shock pro-
teins on the plasma membrane [30]. Although further
studies are needed to determine the exact mechanism
and effector functions caused by the activation of den-
dritic cells by Hsp, Campisi et al. [34] reported that
enhanced production of nitric oxide, TNF-a,I L - 1 b,a n d
IL-6 in rat macrophages and splenocytes response with
Hsp72 stimulation. Moreover, nitric oxide and cytokine
responses were further augmented when cells were
exposed to the combination of Hsp72 plus LPS. This
robust response required five times less Hsp72 than LPS
to produce a nearly equivalent response and evidence
has been reported to show this was not due to endo-
toxin contamination [34]. Hsp’s could be considered
potential targets to prevent tissue injury caused by
trauma-induced cellular stress through this cytokine
activation pathway.
Monosodium Urate
UA is an important Danger signal, whose effects are
mediated by its extracellular release from activated or
necrotic cells. UA has been shown to mediate both
innate and adaptive immune regulatory responses. The
active form of the molecule, monosodium urate crystals,
can trigger inflammation and has been to act as an adju-
vant in promoting dendritic cell maturation and activat-
ing dendritic cell mediated immune responses [16,35].
In vitro, the uptake of monosodium urate crystals by
monocytes involves interactions with Toll like receptors,
specifically TLR2 and TLR4 [36]. Furthermore, the pre-
sence of intracellular monosodium urate crystals has
been shown to activate the innate immune system thru
a range of receptors, specifically of the TLR family, and
proteins that detect pathogens along with damaged or
dying cells through pattern recognition motifs [36]. This
in turn leads to the formation of an inflammasome
complexes that responds to IL-1 to yield mature IL-1b
to be secreted [36]. The inflammatory affects of mono-
sodium urate crystals have been shown to be blocked by
IL-1 inhibition, leading to a rapid and dramatic effect
on the signs and symptoms of inflammation [37]. Thus,
monosodium urate exemplifies the definition of a
DAMP thru its activation of the innate system.
RNA/DNA
CpG rich regions of RNA and DNA have been shown to
bind to TLRs and stimulate cytokine production, and
therefore function as Danger signals. Ishii et al. [38]
demonstrated that double stranded DNA enhanced
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primary cellular and humoral immune response in vivo.
This response was dependent on the length and concen-
tration of double stranded DNA but were independent
of sequence [38]. As mentioned above one of the impor-
tant criteria in identifying a danger associated molecular
pattern is ensuring the purified danger associated mole-
cular pattern is free of endotoxins. When the double
stranded DNA is reduced to single stranded the ability
to induce antigen presenting cell maturation is lost [38].
Antigen presenting cell maturation was also induced by
CpG-containing bacterial DNA in both single and dou-
ble stranded DNA formats [38]. When the single-
stranded bacterial DNA is methylated at the CpG motifs
it no longer capable of stimulating antigen presenting
cell maturation [38].
Mitochondria and their related moieties are an impor-
t a n ts e to fm o l e c u l e st h a tm a yp l a yar o l ea sD A M P s
during sterile inflammation and injury. Because they are
thought to have a genetic makeup that is bacterial in
origin, in theory, injury to cellular structures allowing
for the release of mitochondrial contents into the blood-
stream that would normally stay hidden [39]. Just like
PAMPs, these damage associated mitochondrial patterns
become recognized by PRRs and start the cascade of
inflammatory and immune mediators with eventual
SIRS reaction [40]. This pathway showing release of
mitochondrial contents during injury and leading to
neutrophil migration and degranulation through a TLR
mediated mechanism with subsequent organ injury, has
been show before [40]. Even surgical trauma from femur
fractures showed release of mitochondrial damage asso-
ciated molecular patterns that have the ability to activate
polymorphoneuclear cells in rats, specifically in the lung
[41]. Although the lung injury induced was not as
severe, this does support mitochondrial damage asso-
ciated molecular patterns serving as a priming stumulus
that when hit with a second stimulus, can lead to
further injury to the end organ with increasing inflam-
matory and immunological cascade effects and increased
severity of injury [39].
Toll-like Receptors
The common molecular pathway between sterile injury,
infection and the inflammatory response is thought to
be mediated by stimulation of Toll-Like Receptors
(TLRs) [21]. This family of receptors displays homology
to the Drosophila melanogaster Toll gene product [42]
which is involved in embryogenesis and immunity. By
study of mutations in murine homologues it was shown
that TLR4 is the receptor responsible for the recognition
and inflammatory response to LPS [43]. Subsequent stu-
dies have demonstrated there are approximately12
human TLR homologues and nine murine homologues
[21,44]. These receptors recognize both exogenous and
endogenous Danger molecules as ligands that subse-
quently lead to one of two distinct signaling cascades
that culminate in an activated host inflammatory
response. TLRs recognize a wide variety of exogenous
ligands (PAMPs) through leucine-rich repeats located in
their extracellular domains [45]. Three TLR ligand-
receptor interactions have been elucidited: TLR3/dsRNA
[46], TLR1-TLR2 heterodimers bound to the Pam3CSK4
lipopeptide [47], and TLR4/LPS via the co-receptor
MD-2 [48]. These and other experiments have shown
that TLRs recognize PAMPs via diverse mechanisms
involving homodimerization, heterodimerization, direct
ligand-receptor interactions, accessory molecules and
co-receptors. Further, these multiple complex interac-
tions help to account for the ability of TLRs to recog-
nize such a wide array of Danger molecules.
Endogenous DAMP-TLR interactions have been
reported in vitro, by utilization of immunoprecipitation
assays, in cell culture experiments, and in vivo using
murine models with targeted mutations. For example,
the heat shock proteins Hsp60 and Hsp70 have been
shown to interact directly with TLR-2 and TLR-4 caus-
ing activation of mononuclear cells [49], and HMGB1
requires the co-receptor MD-2 to activate TLR-2 and
TLR-4 [50]. As mentioned previously, monosodium
urate uptake by monocytes has also been shown to be
mediated by interaction with TLR-2 and TLR-4, whereas
dsDNA containing immune complexes cause dendritic
cell maturation through activation of TLR-9. Future stu-
dies using fluorescence resonance energy transfer micro-
scopy and GFP fragment reconstitution to demonstrate
molecular proximity have been proposed [51] and may
provide further in vivo evidence to identify interactions
between endogenous DAMPs and TLR receptors.
When bound by their ligands or ligand complexes,
TLRs are known to activate two distinct signalling path-
ways involved in inflammation. The first uses the signal-
ing adaptor molecule myeloid differentiation factor 88
(MyD88) and is activated by all TLRs with the exception
of TLR3. This signaling cascade is propagated by various
IL-1 receptor associated kinases and mitogen activated
protein kinases and results in NF-b activation which in
turn acts as a direct or indirect (via inflammatory cells)
transcriptional activator of pro-inflammatory cytokine
and chemokine (IL-1a/b, IL-6, IL-8, MIP-1a/b,T N F - a,)
gene expression [16]. This common final pathway may
be the link between sterile tissue injury and infections
thru pathogens, thus allowing us to further understand
the true mechanism behind trauma evoked immunologi-
cal response. The second pathway, activated by ligand
binding of TLR3 and TLR4 is MyD88 independent, and
culminates in the transcriptional activation of interferon
(IFN) [21]. Induction of IFN expression is an additional
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tors of inflammatory and immune responses allowing
for specific cellular responses [21].
Signaling mediated by different TLR pathways has
been demonstrated to lead to different functional
responses. This suggests that TLR signaling is capable of
differential immune responses given varying stimuli
whether from endogenous or exogenous DAMPs [21].
For example, recent studies have shown that HSP60 and
LPS cause differential activation of APC function [52],
and that HMGB1 activation of neutrophils causes up-
regulation Bcl-xl and monoamine oxidase B, which is
not seen in LPS stimulation [53]. Further, microarray
experiments have demonstrated differential inflamma-
tory gene activation in MH-S cells when stimulated with
either the DAMP hyaluronic acid and LPS [54].
T h e s ed a t as u p p o r tam o d e lw h e r ei m m u n es t i m u l a -
tion by exogenous (PAMP’s) and endogenous ("alar-
mins”) DAMPs activate different end pathways [16].
Therefore, different targets for intervention between the
inflammatory response to sterile traumatic or infectious
insult may exist and targeting one alone may help
decrease pathological inflammatory response to injury
while keeping host immune response to infection intact.
Further elucidation of the poorly described intracellular
signaling pathways downstream of TLR activation by
DAMPs may provide insight into key strategies for mod-
ulating maladaptive TLR activation in the injured
patient, while maintaining immunocompetence.
Conclusions & Future Directions
Despite the large amount of research dedicated to multi-
functional danger/alarm signals, much still remains to
be elucidated prior to any discovery of pathways for
therapeutic and immunomodulatory action. In this
review, we have described some of the pathways
whereby Danger molecules lead to an activation of the
innate which causes local inflammation and recruit cells
of the innate immune system and subsequent release of
pro-inflammatory cytokines. It is important to note that
activation of this pathway in turn may results in genera-
tion of a systemic inflammatory response syndrome
(SIRS). In the traumatically injured critically ill patient
this occurs as tissue injury leads to cell necrosis and
release of Danger signals. These DAMPs are thought to
activate TLRs triggering the innate immune response to
release cytokines and other pro-inflammatory mediators
(such as IFN) causing the clinical syndrome of SIRS.
Indeed, plasma levels of HMGB1 after severe injury
have been shown to correlate with development of SIRS,
and early elevation of HMGB1 is associated with
increased mortality [55].
If traumatic SIRS is not attenuated by the compensa-
tory anti-inflammatory response syndrome (CARS) a
deleterious pro-inflammatory cascade may ensue, poten-
tially resulting in MODS and death [56]. Therefore, it is
evident that further investigation of the exact mechan-
ism and role that Danger molecules play in this process
is central for preventing morbidity and mortality asso-
ciated with traumatic injury. Identifying the pathways
involved in the inflammatory response to injury would
enable clinicians to differentiate sterile SIRS from sepsis
and allow for a tailored approach to treatment. Further,
identifying which patients are most likely to develop
severe SIRS after injury may allow for early intervention.
Our current knowledge of Danger signals is incom-
plete and this knowledge gap continues to expand as
new ones emerge. Others that have been added in the
literature thus far include galectins, thymosins, nucleo-
lins, annexins, and thioredoxin [16,57-61], all whose
kinetics, mechanisms, and associations with severe
trauma are still unknown.
Future clinical studies need to be completed to evalu-
ate Danger signals and their associations with outcomes
in trauma. Jastrow et al. [62] provided insight into the
predictive value of cytokine production as an index for
developing future outcomes of multiple organ dysfunc-
tion or failure. As danger/alarmin signals are released in
the acute setting after massive injury, they are the ear-
liest markers of inflammation and may serve to predict
outcomes earlier than other biomarkers. Previous clini-
cal studies have evaluated the correlation between
HMGB1 or Hsp and with outcomes such as survival
and acute lung injury, with intriguing results [63,64].
Future research may wish to focus on the earlier detec-
tion of HMBG1, Hsp, and other Danger signals along
with correlation to various other outcomes to include
multiple organ failure and survival. This would be
important to ascertain the predictive value of detecting
Danger signals versus other previously evaluated bio-
markers of interest.
Finally, clinical trials will be necessary to evaluate for
the possible use of immunomodulation of Danger sig-
nals. Previous pre-clinical experiments in sepsis and
trauma have focused on downstream cytokines in order
to emulate human response [65-68]. These models
demonstrated a decreased inflammatory response when
TNF-a and IL-1 inhibitors were administered following
an endotoxin or gram negative bacteria challenge [66].
Although promising, these results did not translate into
changes in practice as they failed to demonstrate a
decrease in the mortality outcome in Phase II and III
studies [69,70]. One can argue that these studies focused
on downstream cytokines and to really have some effect,
one needs to look to more proximal signaling mechan-
isms to have a therapeutic effect. Even Recombinent
activated protein C (Xigris
®), although approved by the
FDA in 2001 for patients with severe sepsis, some
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increased incidence of bleeding in general clinical use
[71]. Danger/alarmin signals are the most proximal
molecules in the immune response that have many pos-
sibilities for effector function in the innate and acquired
immune systems. Having a full understanding of these
molecules and their pathways would give us the ability
to intervene at such an early stage and may prove to be
more effective in blunting the post-injury inflammatory
response unlike previously failed cytokine experiments.
The impact of effective strategies to limit the immune
response following traumatic injury may be limitless.
N e v e r t h e l e s s ,w ea r en o ta tt h a ts t a g ea n dm u c hs t i l l
remains to be elucidated before these therapeutic strate-
gies can be effective in reality.
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